KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Receivables - Net: 2017-2024

Historic Receivables - Net for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $1.3 billion.

  • Amneal Pharmaceuticals' Receivables - Net rose 19.05% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 19.05%. This contributed to the annual value of $1.3 billion for FY2024, which is 8.65% up from last year.
  • Amneal Pharmaceuticals' Receivables - Net amounted to $1.3 billion in FY2024, which was up 8.65% from $1.2 billion recorded in FY2023.
  • Amneal Pharmaceuticals' 5-year Receivables - Net high stood at $1.3 billion for FY2022, and its period low was $1.2 billion during FY2021.
  • Over the past 3 years, Amneal Pharmaceuticals' median Receivables - Net value was $1.3 billion (recorded in 2024), while the average stood at $1.3 billion.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Receivables - Net fell by 12.17% in 2020, and later climbed by 12.85% in 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' Receivables - Net (Yearly) stood at $1.3 billion in 2020, then decreased by 7.74% to $1.2 billion in 2021, then rose by 12.85% to $1.3 billion in 2022, then fell by 10.78% to $1.2 billion in 2023, then rose by 8.65% to $1.3 billion in 2024.